Shape changes and chemokinesis of Walker carcinosarcoma cells: effects of protein kinase inhibitors (HA-1004, polymyxin B, sangivamycin and tamoxifen) and an inhibitor of diacylglycerol kinase (R 59022).
Previous work has shown that PMA and diacylglycerols, activators of protein kinase C (PKC) can suppress cell polarity and locomotor activity of Walker carcinosarcoma cells in vitro, suggesting that PKC activation may result in a stop signal for tumor cell locomotion. This hypothesis was further analysed. The present results show that the DAG kinase inhibitor, R 59022, suppressed tumor cell polarity and strongly inhibited cell locomotion at a concentration of 10(-4), thus supporting the earlier finding that an increased availability of DAGs can suppress the locomotor activity of Walker carcinosarcoma cells. The results support the stop-signal hypothesis of PKC activation insofar as DAG kinase inhibition mimics the effects of DAGs and PMA. In order to clarify further the effects of protein kinase modulation on locomotion, we now extended our studies on structurally different inhibitors of protein kinases. In contrast to H-7, HA-1004 had no effect on cell polarity and did not reduce cell locomotion in the presence of colchicine, but reduced the proportion of spontaneously locomoting cells by 70% at 3 x 10(-4) M. Polymyxin B suppressed cell polarity and locomotion only at concentrations that proved to be toxic. Tamoxifen had no significant effect on cell polarity and locomotor activity. Sangivamycin did not suppress cell polarity and spontaneous locomotion at a concentration range of 10(-9) M to 10(-4) M. However, at 10(-4) M it decreased the proportion of migrating, colchicine-stimulated cells by 50%. The diverse responses to structurally different PKC inhibitors may be explained by their limited and variable specificity for PKC and different mechanisms of action on PKC.
Institute of Pathology, the University, Bern, Switzerland.
A
A
Zimmermann
H
H
Keller
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D002279:Carcinoma 256, Walker / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology*; D002465:Cell Movement / Q000187:drug effects; D016764:Cell Polarity / Q000187:drug effects; D048429:Cell Size / Q000187:drug effects; D019852:Diacylglycerol Kinase; D007546:Isoquinolines / Q000494:pharmacology; D010770:Phosphotransferases / Q000037:antagonists & inhibitors*; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors; D011112:Polymyxin B / Q000494:pharmacology; D047428:Protein Kinase Inhibitors; D011741:Pyrimidine Nucleosides / Q000494:pharmacology; D011744:Pyrimidinones / Q000494:pharmacology*; D013268:Stimulation, Chemical; D013449:Sulfonamides; D013629:Tamoxifen / Q000494:pharmacology; D013844:Thiazoles / Q000494:pharmacology*; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000903:Antibiotics, Antineoplastic; D007546:Isoquinolines; D010972:Platelet Activating Factor; D047428:Protein Kinase Inhibitors; D011741:Pyrimidine Nucleosides; D011744:Pyrimidinones; D013449:Sulfonamides; D013844:Thiazoles; D013629:Tamoxifen; C005699:sangivamycin; C043204:N-(2-guanidinoethyl)-5-isoquinolinesulfonamide; C047505:R 59022; D010770:Phosphotransferases; D019852:Diacylglycerol Kinase; D011112:Polymyxin B